"The filing of the provisional patent on our breakthrough
detection of TB and HIV-DNA in the urine of AIDS patients marks a
continued step in our strategy to aggressively expand the Company's
intellectual property portfolio and to protect that property with
broad and well -enforced U.
Randy White, CEO of Xenomics. Through filings such as this, Dr. Xenomics has three issued U.html

Forward-Looking Statements

Certain statements made in this press release are forward looking. Mr.D.L.R.com.

syndrome zellweger

trilogy-capital. Although Xenomics believes that the expectations
reflected in such forward-looking statements are reasonable, it can
give no assurance that such expectations reflected in such
forward-looking statements will prove to be correct.
(OTCBB:XNOM), a developer of next-generation medical DNA technologies,
will be presenting at the world's first workshop on Transrenal-DNA
diagnostics, a revolutionary field of medical research that Xenomics
is pioneering with its patented technology platform. The Company believes that its
technology will open significant new markets in the molecular
diagnostics field.

zollinger health

S.trilogy-capital.

Immtech Appoints Daniel Schmitt Vice President Licensing and Commercial Development

Prior to joining Immtech, Mr .'s
business which are not historical facts are "forward-looking statements" that
involve risks and uncertainties.com/tcp/xenomics/ny1_video.

disorders conditions

Business Editors

NEW YORK----Xenomics, Inc . The Company believes that its
technology will open significant new markets in the molecular
diagnostics field.R. VERNON HILLS, Ill., head of research for Xenomics in Rome and
President of SpaXen Italia , S. The Company has organized a joint venture to conduct
research on infectious disease detection with the National Institute
for Infectious Diseases (Instituto Nazionale per le Malattie Infettive
"Lazarus Spallanzani") in Rome, in the form of a new R+D company
called SpaXen Italia, S. A TV news
report about the Company's next-generation prenatal tests can be
viewed at http://www.

zoonoses ellison

The discovery was made at
the Company's joint venture with the National Institute for Infectious
Diseases "Lazzaro Spallanzani" in Rome.
Xenomics' patented technology uses safe and simple urine collection
and can be applied to a broad range of applications, including
prenatal testing, tumor detection and monitoring, tissue
transplantation, infectious disease detection, genetic testing for
forensic identity determination, drug development, and research to
counter bioterrorism.html. Mr. Schmitt has over 17 years of pharmaceutical industry experience, with
roles in both large pharmaceutical and small biotechnology companies. Schmitt has
over 10 years of licensing and business development experience, and has
executed several successful commercial and research collaborations with large
pharmaceutical, biotech, and leading academic and research institutions. Schmitt assumed his new responsibilities upon the departure of David
Tiemeier who, for family reasons, has resigned from the Company to relocate to
another city.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995:
Statements in this press release regarding Immtech International, Inc.L. We are eager
to share and discuss our latest advances with our colleagues.
L.

Xenomics is a molecular diagnostic company that focuses on the
development of DNA-based tests using Transrenal DNA (Tr-DNA ). patents covering
different applications of the technology for molecular diagnostics and
genetic testing and a pending European patent for the same
applications.

ulcer conditions

The Italian patent application, which paves the way for the
filing of European and American patents, represents the Company's
latest step in its business strategy to aggressively expand and
protect its intellectual property portfolio . Through its patented
Transrenal DNA-based technology platform, the Company is developing a
range of tests for infectious diseases including AIDS and
tuberculosis, for prenatal genetic testing, including gender
determination, Rh incompatibility and Down syndrome, and other
applications. patents covering
different applications of the technology for molecular diagnostics and
genetic testing and a pending European patent for the same
applications., Immtech
International, Inc. Dan has already
made significant contributions to the Company and we look forward to
leveraging his talents and experience as we move DB289, our first oral drug
candidate, toward commercialization. In recent weeks, Xenomics has
announced a number of important clinical results, including the
demonstration of the ability to detect both the presence of HIV
residual disease and tuberculosis in urine samples of AIDS patients ,
including the equally important ability to detect them simultaneously
in a single specimen. We also
look forward to publicly recognizing the valuable support we have
received from the Istituo Nazionale per le Malattie Infettive here in
Rome.

zellweger conditions

(OTCBB:XNOM), a developer of next-generation medical DNA technologies,
has filed a provisional patent in Italy for its breakthrough
technology enabling the detection of Transrenal-DNA of HIV and
tuberculosis through the safe and non-invasive process of urine
sampling. The technology also provides
breakthrough ability to simultaneously detect both HIV and
tuberculosis, a common co-infection in AIDS patients, with a single
urine sample, and may hold important implications for the detection
and treatment of residual HIV infections . Schmitt worked at First Genetic Trust (FGT)
as Director of Academic Partnerships, where he was responsible for developing
collaborations in cutting edge genomic research.
Mr. We are developing treatments for fungal infections, malaria,
tuberculosis, cancer, diabetes, Pneumocystis pneumonia ("PcP") and tropical
diseases, including African sleeping sickness (trypanosomiasis) and
leishmaniasis. Xenomics ' breakthrough technology enables detection
of DNA using safe, simple and non-invasive urine collection , which
offers a number of significant advantages over current techniques that
require blood or tissue sampling.com/tcp/xenomics/factsheet.trilogy-capital.

syndrome digestive

patent."
Xenomics is developing and commercializing proprietary gateway DNA
testing technology that has the potential to significantly expand the
field of molecular diagnostics, currently a $1. Scientists from Xenomics were the first to
report that fragments of DNA from normal cell death cross the kidney
barrier and can be detected in urine.trilogy-capital. To view an
online video about Xenomics technology and products, visit
http: //www.trilogy-capital.
Such statements are indicated by words such as "expect," "might,"
"should ," "anticipate" and similar words indicating uncertainty in
facts and figures. We have a
worldwide , exclusive license to commercialize a dicationic pharmaceutical
platform from which a pipeline of products may be developed to target large,
global markets.R. For more investor-specific information , including
daily and historical Company stock quote data and recent news
releases, please visit http://www.
Such statements are indicated by words such as "expect," "might,"
"should," "anticipate " and similar words indicating uncertainty in
facts and figures.

conditions ellison

The initial filing will lead to
the filing of the broader European patent, and then to the U.com/tcp/xenomics. To
read or download the Company's Investor Fact Sheet visit
http://www.com/tcp/xenomics/ny1_video. He
brings significant commercial expertise to the position, gained through
leadership roles in market research, forecasting , product planning and
business development. He has successfully developed and led cross-functional
development teams, and has participated in or led the commercial development
and launch of more than a dozen new pharmaceutical products.
T.

"
Xenomics scientists were the first to report that fragments of DNA
arising from normal cell death cross through the kidney, or renal ,
barrier and can be detected in urine.S.L. To view an
online video about Xenomics technology and products, visit
http://www.com/tcp/xenomics/video.

zollinger z

Because the technology was developed in Italy , international
patent regulations require that the patent be initially filed in that
country where the discovery was made.S.5 billion segment of
the health care and biotechnology industry. The Company has organized a joint venture to conduct
research on infectious disease detection with the National Institute
for Infectious Diseases (Instituto Nazionale per le Malattie Infettive
"Lazarus Spallanzani ") in Rome, in the form of a new R+D company
called SpaXen Italia, S. Prior to FGT, Mr. To
read or download the Company's Investor Fact Sheet visit
http://www.html

Forward-Looking Statements

Certain statements made in this press release are forward looking.

zoonoses zellweger

"To manage this critical area, we
recently established our Department of Licensing and Intellectual
Property, and appointed veteran patent agent Dr.

About Xenomics, Inc. A TV news
report about the Company 's next-generation prenatal tests can be
viewed at http://www. Schmitt
was Director, Global Oncology at Searle/Pharmacia, where he headed the teams
responsible for developing commercialization strategies for Searle's programs
in anti-angiogenesis and immunotherapy, including cancer vaccines.
Xenomics is hosting the workshop as part of its joint venture with
the National Institute for Infectious Diseases (Instituto Nazionale
per le Malattie Infettive "Lazarus Spallanzani"), based in Rome,
Italy. Xenomics ' joint venture, established to conduct research on
infectious disease detection, has been established as the research and
development company SpaXen Italia, S.
Chief scientists and officers from Xenomics will present results
of recent HIV and TB clinical studies involving its proprietary
Transrenal -DNA (Tr-DNA) medical testing technology, and will outline
its plan to continue to carry out the clinical studies necessary to
bring products to the biomedical marketplace. Randy White, CEO of Xenomics.

health digestive

The Company believes that this application of its patented
technology development platform may enable the creation of more
sensitive and accurate medical testing methods that can be conducted
through the simple, safe and relatively inexpensive diagnostic
processes based on urine specimens . David Ladner to lead
the department.html.com/tcp/xenomics/video.
Mr."

About Immtech International
Immtech International, Inc.

Business Editors/Health/Medical Writers/Biotech Writers

NEW YORK----Xenomics, Inc.
Xenomics' patented technology uses safe and simple urine collection
and can be applied to a broad range of applications, including
prenatal testing, tumor detection and monitoring, tissue
transplantation, infectious disease detection, genetic testing for
forensic identity determination, drug development, and research to
counter bioterrorism.

digestive ulcer

and international patents," said Dr. Ladner is
spearheading the expansion of our intellectual property portfolio.S . For more information, please visit
http://xenomics. As discussed in
the periodic reports of Xenomics , as filed with the Securities and
Exchange Commission, actual results could differ materially from those
projected in the forward-looking statements as a result of the
following factors, among others: uncertainties associated with product
development, the risk that Xenomics will not obtain approval to market
its products, the risk that Xenomics' technology will not gain market
acceptance , the risks associated with dependence upon key personnel,
and the need for additional financing.

(Amex: IMM) announced today that Daniel Schmitt has been
appointed to the newly-created position of Vice President, Licensing and
Commercial Development. Stephen Thompson, President and CEO said , "We are pleased that Dan will
be spearheading our licensing and commercial development.
"Our research involving HIV, TB and other infectious diseases has
already produced important new clinical data that demonstrates the
potential to significantly transform, simplify and improve the
fast -growing marketplace of DNA-based diagnostic testing., added, "This special workshop will
help the marketplace understand the vast business and medical
implications of the new field of Transrenal DNA diagnostic testing
being developed by scientists at Xenomics and Spaxen Italia.

ellison stomach

L. For more investor -specific information, including
daily and historical Company stock quote data and recent news
releases , please visit http://www. For a discussion of such risks and
uncertainties that could cause actual results to differ from those contained
in the forward-looking statements, see "Risk Factors" in the Company's Annual
Report on Form 10-K/A for the most recently ended fiscal year.

Xenomics to Host First Annual Workshop on Transrenal-DNA Diagnostics at Spaxen Italia Research Institute; Company to Present Business and Scientific Review of

"This meeting has drawn medical researchers from around the world
that are working in the groundbreaking field of Tr-DNA diagnostics and
see the enormous potential ," said Dr.

About Xenomics, Inc. Scientists from Xenomics were the first to
report that fragments of DNA from normal cell death cross the kidney
barrier and can be detected in urine. For more information , please visit
http://xenomics.com/tcp/xenomics.html. Although Xenomics believes that the expectations
reflected in such forward-looking statements are reasonable, it can
give no assurance that such expectations reflected in such
forward-looking statements will prove to be correct. As discussed in
the periodic reports of Xenomics, as filed with the Securities and
Exchange Commission, actual results could differ materially from those
projected in the forward-looking statements as a result of the
following factors, among others: uncertainties associated with product
development, the risk that Xenomics will not obtain approval to market
its products, the risk that Xenomics' technology will not gain market
acceptance, the risks associated with dependence upon key personnel,
and the need for additional financing.

zoonoses peptic

com/tcp/xenomics/factsheet. Schmitt joined Immtech in November and will be
responsible for overseeing licensing and commercialization activities related
to the Company 's proprietary medicinal chemistry platform. David Tomei, Ph."
The Company is using its patented Transrenal DNA-based technology
platform to develop a number of medical tests for infectious diseases
including AIDS and tuberculosis, and for important prenatal genetic
testing, including gender determination , Rh factor incompatibility,
and Down syndrome.trilogy-capital.html.

genetic infectious

Xenomics Files Italian National Patent on Testing Technology to Detect HIV and Tuberculosis Using Transrenal DNA; Proprietary Diagnostic Tests Enable Simultane

Xenomics is a molecular diagnostic company that focuses on the
development of DNA-based tests using Transrenal DNA (Tr-DNA).com. is a pharmaceutical company advancing the
development and commercialization of oral drugs to treat infectious diseases
and neoplastic (cancer) and metabolic (diabetes) disorders. Xenomics has three issued U.trilogy-capital.trilogy-capital.